{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:28:18Z","timestamp":1770182898182,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jocd.2025.101641","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:37:27Z","timestamp":1761356247000},"page":"101641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adherence and persistence of daily and twice-weekly teriparatide treatment in postmenopausal women with high-risk of fracture"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8316-8671","authenticated-orcid":false,"given":"Takeshi","family":"Mochizuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-2719","authenticated-orcid":false,"given":"Koichiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2025.101641_bib0001","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jocd.2025.101641_bib0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","article-title":"Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study","volume":"34","author":"Schuit","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2025.101641_bib0003","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","article-title":"Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis","volume":"15","author":"Klotzbuecher","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2025.101641_bib0004","doi-asserted-by":"crossref","first-page":"dgaa048","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2025.101641_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jocd.2025.101641_bib0006","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2025.101641_bib0007","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jocd.2025.101641_bib0008","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2025.101641_bib0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2025.101641_bib0010","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1185\/03007990902790993","article-title":"Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment","volume":"25","author":"Prevrhal","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocd.2025.101641_bib0011","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s00198-019-05111-6","article-title":"Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study","volume":"30","author":"Sugimoto","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.afos.2020.12.001","article-title":"Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: a post hoc analysis of the TWICE study","volume":"7","author":"Sugimoto","year":"2021","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.jocd.2025.101641_bib0013","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00774-020-01186-y","article-title":"Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels","volume":"39","author":"Takada","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jocd.2025.101641_bib0014","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1185\/03007990903538409","article-title":"Adherence and persistence in patients with severe osteoporosis treated with teriparatide","volume":"26","author":"Ziller","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocd.2025.101641_bib0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00774-015-0653-7","article-title":"Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: minodroate Alendronate\/risedronate Trial in Osteoporosis (MARTO)","volume":"34","author":"Iwamoto","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jocd.2025.101641_bib0016","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11657-015-0231-6","article-title":"Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA","volume":"10","author":"Kishimoto","year":"2015","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.jocd.2025.101641_bib0017","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00198-014-2756-8","article-title":"Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study","volume":"25","author":"Sakai","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0018","first-page":"423","article-title":"Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study","volume":"35","author":"Calvo-Al\u00e9n","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jocd.2025.101641_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015872","article-title":"Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database","volume":"7","author":"Bhoi","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jocd.2025.101641_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00198-016-3736-y","article-title":"Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)","volume":"28","author":"Nakamura","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jocd.2025.101641_bib0022","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00198-016-3886-y","article-title":"Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years","volume":"28","author":"Modi","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0023","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s00198-016-3611-x","article-title":"Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database","volume":"27","author":"Chan","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115838","article-title":"Persistence with osteoporosis treatment in patients from the Lille University Hospital Fracture Liaison Service","volume":"144","author":"Delbar","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2025.101641_bib0025","first-page":"247","article-title":"The Italian Observational Study on Severe Osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment","volume":"34","author":"Idolazzi","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jocd.2025.101641_bib0026","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1620\/tjem.2023.J022","article-title":"Comparison of the continuation rate of twice-weekly and weekly teriparatide administration in a rural area","volume":"260","author":"Tsuchie","year":"2023","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.jocd.2025.101641_bib0027","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","article-title":"Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures","volume":"15","author":"Oleksik","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2025.101641_bib0028","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00198-017-4296-5","article-title":"Vertebral fractures and their association with health-related quality of life, back pain and physical function in older women","volume":"29","author":"Johansson","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0029","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00198-019-04963-2","article-title":"Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study","volume":"30","author":"Borek","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","article-title":"Determinants of adherence to osteoporosis treatment in clinical practice","volume":"17","author":"Rossini","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/654218","article-title":"Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study","volume":"2013","author":"Tanaka","year":"2013","journal-title":"J Osteoporos"},{"key":"10.1016\/j.jocd.2025.101641_bib0032","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","article-title":"Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis","volume":"21","author":"Imaz","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2025.101641_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116416","article-title":"Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: the TERABIT study","volume":"160","author":"Chiba","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2025.101641_bib0034","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1210\/en.2015-2028","article-title":"Frequency of teriparatide administration affects the histological pattern of bone formation in young adult male mice","volume":"157","author":"Yamamoto","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.jocd.2025.101641_bib0035","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3390\/nu15132991","article-title":"Can nutrition contribute to a reduction in sarcopenia, frailty, and comorbidities in a super-aged society?","volume":"15","author":"Yoshida","year":"2023","journal-title":"Nutrients"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695025000794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695025000794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:11:52Z","timestamp":1770135112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695025000794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1094695025000794"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2025.101641","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence and persistence of daily and twice-weekly teriparatide treatment in postmenopausal women with high-risk of fracture","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2025.101641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The International Society for Clinical Densitometry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101641"}}